FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
BREAKING NEWS
Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.
| READ NOW |
Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.
| READ NOW |